Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., ...

“Andrew’s extensive capital markets and in-house finance experience make him a strong addition to the Pelthos Board of Directors,” said Peter Greenleaf, Chairman of the Board. “His experience ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, announced ...

The securities issued and issuable, described in this and the previous news release on November 6, 2025, will be subject to a statutory hold period of four months plus a day from the date of issuance ...

Authorization for the Reverse Split was approved by the Company’s stockholders at SeaStar Medical’s 2025 Special Meeting of Stockholders held on December 18, 2025. The objective of the Reverse Split ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and ...

Harvard-trained orthodontist offers complimentary 15-minute airway analysis to help identify hidden causes of childhood focus problems. LOS ANGELES, Dec. 23, 2025 (GLOBE NEWSWIRE) ...

LA JOLLA, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Singlera Genomics, a company focused on the development and application of novel DNA methylation technologies to genetic diagnosis, today announced ...

Ghent, Belgium, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan PRESS RELEASE REGULATED INFORMATION / INSIDE INFORMATION 23 ...

ICP-488 is an oral, potent, and selective TYK2 allosteric inhibitor. By binding to the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN, and other inflammatory cytokines, ...

LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company developing first-in-class, orally delivered immune-tolerance-restoring therapies, announced today that the first patient ...

As part of the segment, Brad Hauser, CEO of Autonomix, outlined two key priorities shaping the Company’s trajectory: strengthening its platform through intellectual property protection and evaluating ...